undamentalytics Newsletter

Immix Biopharma, Inc. valuation and forecast

Explore the models for Immix Biopharma, Inc., adjust their assumptions and compare your own valuation with the platform's.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Immix Biopharma, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: limited reported history: available models are shown without a Buy/Hold/Sell rating. We'll show the comparison once resolved.

Analyst recommendations

7 analysts, Oct 2026
Buy7100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026347
  2. Sep 2026347
  3. Aug 2026347
  4. Jul 2026347

Counts of recommendations published by analysts covering Immix Biopharma, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Price history

Loading chart…

Third-party market data · may be delayed

IMMX valuation questions

How does Fundamentalytics value Immix Biopharma, Inc.?
We use the models that fit Immix Biopharma, Inc.'s business and available financial data. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.

Data: SEC EDGAR filings, retrieved Invalid Date. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Immix Biopharma, Inc.